- Home
- UPWK vs ETNB Comparison
UPWK vs ETNB Comparison
Compare UPWK & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPWK
- ETNB
- Stock Information
- Founded
- UPWK 2013
- ETNB 2018
- Country
- UPWK United States
- ETNB United States
- Employees
- UPWK N/A
- ETNB N/A
- Industry
- UPWK EDP Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- UPWK Technology
- ETNB Health Care
- Exchange
- UPWK Nasdaq
- ETNB Nasdaq
- Market Cap
- UPWK 1.8B
- ETNB 1.5B
- IPO Year
- UPWK 2018
- ETNB 2019
- Fundamental
- Price
- UPWK $15.39
- ETNB $9.03
- Analyst Decision
- UPWK Buy
- ETNB Strong Buy
- Analyst Count
- UPWK 14
- ETNB 9
- Target Price
- UPWK $18.77
- ETNB $26.63
- AVG Volume (30 Days)
- UPWK 3.6M
- ETNB 1.6M
- Earning Date
- UPWK 08-06-2025
- ETNB 08-07-2025
- Dividend Yield
- UPWK N/A
- ETNB N/A
- EPS Growth
- UPWK 220.06
- ETNB N/A
- EPS
- UPWK 1.72
- ETNB N/A
- Revenue
- UPWK $772,904,000.00
- ETNB N/A
- Revenue This Year
- UPWK $2.45
- ETNB N/A
- Revenue Next Year
- UPWK $5.37
- ETNB N/A
- P/E Ratio
- UPWK $8.94
- ETNB N/A
- Revenue Growth
- UPWK 3.92
- ETNB N/A
- 52 Week Low
- UPWK $8.91
- ETNB $4.16
- 52 Week High
- UPWK $18.14
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- UPWK 68.76
- ETNB 43.91
- Support Level
- UPWK $14.70
- ETNB $9.07
- Resistance Level
- UPWK $15.13
- ETNB $9.62
- Average True Range (ATR)
- UPWK 0.43
- ETNB 0.42
- MACD
- UPWK 0.16
- ETNB 0.03
- Stochastic Oscillator
- UPWK 99.03
- ETNB 31.63
About UPWK Upwork Inc.
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to clients.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).